Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Combination therapy
US9408847B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9408847-B2 |
| Application number | US-201314646206-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 25, 2013 |
| Priority date | Nov 28, 2012 |
| Publication date | Aug 9, 2016 |
| Grant date | Aug 9, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating ER+ breast cancer comprising administering to a subject in need of such treatment a combination comprising a first agent that is a cyclin dependent kinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a second agent that is an mTOR inhibitor. 2. The method of claim 1 , wherein the agents are administered simultaneously, separately or sequentially. 3. The method of claim 1 , wherein the CDK inhibitor is CDK4/6 inhibitor. 4. The method of claim 3 , wherein the CDK4/6 inhibitor is Compound A, described by Formula A below: or pharmaceutically acceptable salt thereof. 5. The method of claim 1 , wherein the mTOR inhibitor is everolimus. 6. A method of treating malignant rhabdoid tumor comprising administering to a subject in need of such treatment a combination comprising a first agent that is a cyclin dependent kinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a second agent that is an mTOR inhibitor. 7. The method of claim 6 , wherein the agents are administered simultaneously, separately or sequentially. 8. The method of claim 6 , wherein the CDK inhibitor is CDK4/6 inhibitor. 9. The method of claim 8 , wherein the CDK4/6 inhibitor is Compound A, described by Formula A below: or pharmaceutically acceptable salt thereof. 10. The method of claim 6 , wherein the mTOR inhibitor is everolimus.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title
- A61K31/519Primary
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9408847B2 cover?
- The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof.
- Who is the assignee on this patent?
- Doshi Shivang, Kim Sunkyu, Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).